American Society of Clinical Oncology. The state of cancer care in America, 2017: A report by the American Society of Clinical Oncology. J Oncol Pract 2017;13(4):e353-e394. Abstract

Blackwell K et al. Pooled analysis of two randomized, double-blind trials comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer. Ann Oncol 2017;28(9):2272-7. Abstract

Blackwell K et al. Comparison of EP2006, a filgrastim biosimilar, to the reference: A phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy. Ann Oncol 2015;26(9):1948-53. Abstract

Casak SJ et al. FDA’s approval of the first biosimilar to bevacizumab. Clin Cancer Res 2018;24(18):4365-70. Abstract

Cohen H et al. Awareness, knowledge, and perceptions of biosimilars among specialty physicians. Adv Ther 2017;33(12):2160-72. Abstract

Cuello HA et al. Comparability of antibody-mediated cell killing activity between a proposed biosimilar RTXM83 and the originator rituximab. BioDrugs 2016;30(3):225-31. Abstract

Dougherty MK et al. Perspectives on the current state of the biosimilar regulatory pathway in the United States. Clin Pharmacol Ther 2018;103(1):36-8. Abstract

Farhat F et al. The concept of biosimilars: From characterization to evolution — A narrative review. Oncologist 2018;23(3):346-52. Abstract

Franceschetti A, Caldeira R. Treatment approach for non-Hodgkin lymphoma patients since first biosimilars of rituximab approved in EU5. Proc ASCO 2018;Abstract 112.

Frank RG. Friction in the path to use of biosimilar drugs. N Engl J Med 2018;378(9):791-3. Abstract

Hakim A, Ross JS. Obstacles to the adoption of biosimilars for chronic diseases. JAMA 2017;317(21):2163-4. Abstract

Harbeck N et al. Comparison of efficacy and safety of biosimilar filgrastim in a RCT (PIONEER) and real-world practice (MONITOR-GCSF). Proc ASCO 2018;Abstract 111.

Harvey RD. Science of biosimilars. J Oncol Pract 2017;13(9 Supp):17-23. Abstract

Jurczak W et al. Equivalent efficacy of a biosimilar rituximab and reference rituximab in previously untreated advanced follicular lymphoma: Extended results of ASSIST-FL, a confirmatory phase III study. Proc ESMO 2017;Abstract 994O.

Jurczak W et al. Rituximab biosimilar and reference rituximab in patients  with previously untreated advanced follicular lymphoma (ASSIST-FL): Primary results from a confirmatory phase 3, double-blind, randomised, controlled study. Lancet Haematol 2017;4(8):e350-61. Abstract

Kim WS et al. Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: A randomised, double-blind, parallel-group, non-inferiority phase 3 trial. Lancet Haematol 2017;4(8):e362-73. Abstract

Lyman GH et al. American Society of Clinical Oncology Statement: Biosimilars in oncology. J Clin Oncol 2018;36(12):1260-5. Abstract

Lyman GH et al. Rationale, opportunities, and reality of biosimilar medications. N Engl J Med 2018;378(21):2036-44. Abstract

Lyman GH et al. In discussion of: Rationale, opportunities, and reality of biosimilar medications. N Engl J Med 2018;379(7):694-5. Abstract

Manikhas A et al. Biosimilar trastuzumab-dkst monotherapy versus trastuzumab monotherapy after combination therapy: Toxicity, efficacy, and immunogenicity from the phase 3 Heritage trial. Proc ASCO 2018;Abstract 110.

Markus R et al. Developing the totality of evidence for biosimilars: Regulatory considerations and building confidence for the healthcare community. BioDrugs 2017;31(3):175-87. Abstract

Nabhan C, Feinberg BA. Behavioral economics and the future of biosimilars. J Natl Compr Canc Netw 2017;15(12):1449-51. Abstract

Romera A et al. Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: A multicentre, open-label, randomised controlled trial. Lancet Gastroenterol Hepatol 2018;[Epub ahead of print]. Abstract

Rugo HS et al; Heritage Study Investigators. Effect of a proposed trastuzumab biosimilar compared with trastuzumab on overall response rate in patients with ERBB2 (HER2)-positive metastatic breast cancer: A randomized clinical trial. JAMA 2017;317(1):37-47. Abstract

Rugo HS et al. A clinician’s guide to biosimilars in oncology. Cancer Treat Rev 2016;46:73-9. Abstract

Sörgel F et al. Comparability of biosimilar filgrastim with originator filgrastim: Protein characterization, pharmacodynamics, and pharmacokinetics. BioDrugs 2015;29(2):123-31. Abstract

Waller CF et al. A pharmacokinetics and pharmacodynamics equivalence trial of the proposed pegfilgrastim biosimilar, MYL-1401H, versus reference pegfilgrastim. J Cancer Res Clin Oncol 2018;144(6):1087-95. Abstract